MR. TEH WING KWAN
Non-Executive and Non-Independent Chairman
Board of DirectorsThe business, the people and the ownership behind Livingstone.
Business overview
Livingstone Health provides specialist healthcare and primary healthcare services. These activities form its principal reportable operating segments.
Listed security
Board & management
Non-Executive and Non-Independent Chairman
Board of DirectorsExecutive Director and Chief Executive Officer
Board of Directors; CEOExecutive Director and Chief Commercial Officer
Board of DirectorsLead Independent and Non-Executive Director
Board of DirectorsIndependent and Non-Executive Director
Board of DirectorsRoles listed in Livingstone Health Holdings Limited Annual Report 2026; current appointments are not independently verified.
Holdings
Direct 48,466,200 shares (7.69%); deemed 258,373,267 shares (40.97%); total 306,839,467 shares (48.66%)
Substantial shareholdings; % based on 630,592,000 sharesDirect 10,499,576 shares (1.67%); deemed nil; total 10,499,576 shares (1.67%)
Substantial shareholdings table (director); % based on 630,592,000 sharesNo direct or deemed interest (–)
Substantial shareholdings table (director); % based on 630,592,000 sharesNo direct or deemed interest (–)
Substantial shareholdings table (director); % based on 630,592,000 sharesDirect 258,373,267 shares (40.97%); deemed nil; total 258,373,267 shares (40.97%)
Substantial Shareholders (Other than Directors); % based on 630,592,000 sharesDirect 24,183,900 shares (3.84%); deemed 258,373,267 shares (40.97%); total 282,557,167 shares (44.81%)
Substantial Shareholders (Other than Directors); % based on 630,592,000 sharesTotal interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.
Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. As reported at 2026-06-16 · PDF p. 162
| Registered holder | Interest | Shares / units | Source |
|---|---|---|---|
| LIVINGSTONE HEALTH CONSOLIDATED PTE. LTD. | Rank 1; 258,373,267 shares; 40.97% | PDF p. 1622026-06-16 | |
| TAY CHING YIT WILSON | Rank 2; 48,466,200 shares; 7.69% | PDF p. 1622026-06-16 | |
| DBS NOMINEES (PRIVATE) LIMITED | Rank 3; 32,929,470 shares; 5.22% (nominee) | PDF p. 1622026-06-16 | |
| CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD. | Rank 4; 28,526,134 shares; 4.52% | PDF p. 1622026-06-16 | |
| CHUA MENG HUI, SEBASTIAN(CAI MINGHUI, SEBASTIAN) | Rank 5; 24,183,900 shares; 3.84% | PDF p. 1622026-06-16 | |
| LIM PANG YEN RACHEL | Rank 6; 23,410,080 shares; 3.71% | PDF p. 1622026-06-16 | |
| CHUA HSHAN CHER | Rank 7; 22,364,035 shares; 3.55% | PDF p. 1622026-06-16 | |
| LEE KAI LUN | Rank 8; 20,826,963 shares; 3.30% | PDF p. 1622026-06-16 | |
| LIU HUA | Rank 9; 16,193,400 shares; 2.57% | PDF p. 1622026-06-16 | |
| PHILLIP SECURITIES PTE LTD | Rank 10; 13,656,757 shares; 2.17% | PDF p. 1622026-06-16 | |
| DAX NG YUNG SERN (DAX HUANG YONGSHENG) | Rank 11; 10,499,576 shares; 1.67% | PDF p. 1622026-06-16 | |
| MAYBANK SECURITIES PTE. LTD. | Rank 12; 10,236,624 shares; 1.62% | PDF p. 1622026-06-16 | |
| CHENG KWEE THIAM (ZHONG GUITIAN) | Rank 13; 6,307,100 shares; 1.00% | PDF p. 1622026-06-16 | |
| ICH CAPITAL PTE LTD | Rank 14; 5,935,560 shares; 0.94% | PDF p. 1622026-06-16 | |
| KGI SECURITIES (SINGAPORE) PTE. LTD | Rank 15; 5,476,380 shares; 0.87% | PDF p. 1622026-06-16 | |
| OCBC SECURITIES PRIVATE LIMITED | Rank 16; 5,302,786 shares; 0.84% | PDF p. 1622026-06-16 | |
| FOONG CHING CHING ANGELA | Rank 17; 4,877,746 shares; 0.77% | PDF p. 1622026-06-16 | |
| TAN KIM YEOW | Rank 18; 4,655,600 shares; 0.74% | PDF p. 1622026-06-16 | |
| TAN MARK TERENCE | Rank 19; 3,800,000 shares; 0.60% | PDF p. 1622026-06-16 | |
| LEE WEE NGAM | Rank 20; 3,600,000 shares; 0.57% | PDF p. 1622026-06-16 | |
| TOTAL | 549,621,578 shares; 87.16% | PDF p. 1622026-06-16 | |
Group structure
| Company | Market | Ownership interest |
|---|---|---|
| Livingstone Health Ltd. (“LHL”)(1)Held directly by the CompanyPDF p. 130 | Singapore | |
| Livingstone Health Ltd. (“LHL”)(1)Held directly by the Company; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Precision Medical Services Pte. Ltd.(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Precision Medical Services Pte. Ltd.(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Livingstone Endocrine Pte. Ltd.(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Livingstone Endocrine Pte. Ltd.(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| The Bone and Joint Centre Pte. Ltd.(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| The Bone and Joint Centre Pte. Ltd.(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Al Tirah Anaesthesia Services Pte. Ltd.(1) (“ATAS”)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Al Tirah Anaesthesia Services Pte. Ltd.(1) (“ATAS”)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 51; 2025: 51 | |
| RL Aesthetics Pte. Ltd. (“RL”)(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| RL Aesthetics Pte. Ltd. (“RL”)(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Apicare Pain Specialist Pte. Ltd. (“APS”)(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Apicare Pain Specialist Pte. Ltd. (“APS”)(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Sebastian Chua MH Pte. Ltd.(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Sebastian Chua MH Pte. Ltd.(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Cove Sports & Reconstruction Pte. Ltd.(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Cove Sports & Reconstruction Pte. Ltd.(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| LSH SurgiSuites Pte. Ltd.(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| LSH SurgiSuites Pte. Ltd.(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Livingstone Health International Pte. Ltd. (“LHI”)(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Livingstone Health International Pte. Ltd. (“LHI”)(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Phoenix Medical Group Pte. Ltd. (“PMG”)(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Phoenix Medical Group Pte. Ltd. (“PMG”)(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Livingstone Gastroenterology & Liver Pte. Ltd.(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Livingstone Gastroenterology & Liver Pte. Ltd.(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Prism Partnerships (SG) Pte. Ltd.(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Prism Partnerships (SG) Pte. Ltd.(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Quantum Orthopaedics Pte. Ltd. (“QO”)(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Quantum Orthopaedics Pte. Ltd. (“QO”)(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 51; 2025: 51 | |
| Allied Health Partners Pte. Ltd.(1) (fka Virtuemed Pte. Ltd. (“VM”))Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Allied Health Partners Pte. Ltd.(1) (fka Virtuemed Pte. Ltd. (“VM”))Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: –; 2025: 51 | |
| Cove Dermatology Pte. Ltd.(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Cove Dermatology Pte. Ltd.(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 100; 2025: 100 | |
| Phoenix Healthcare Solutions Pte. Ltd. (“PHS”)(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Phoenix Healthcare Solutions Pte. Ltd. (“PHS”)(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 51; 2025: 51 | |
| Atlas Podiatry Pte. Ltd.(1)Held through Livingstone Health Ltd.PDF p. 130 | Singapore | |
| Atlas Podiatry Pte. Ltd.(1)Held through Livingstone Health Ltd.; effective equity held by the Group; 2026 vs 2025PDF p. 130 | 2026: 85; 2025: 85 | |
| Venture Investment Pte. Ltd. (“VIPL”)(2)Held through LHIPDF p. 131 | Singapore | |
| Venture Investment Pte. Ltd. (“VIPL”)(2)Held through LHI; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: –; 2025: 100 | |
| Atlas Physiotherapy Pte. Ltd.(3)Held through VIPLPDF p. 131 | Singapore | |
| Atlas Physiotherapy Pte. Ltd.(3)Held through VIPL; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: –; 2025: 100 | |
| Cove Aesthetics T Pagar Pte. Ltd.(1)Held through RLPDF p. 131 | Singapore | |
| Cove Aesthetics T Pagar Pte. Ltd.(1)Held through RL; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: 100; 2025: 100 | |
| PMG HV Pte. Ltd.(1)Held through PMGPDF p. 131 | Singapore | |
| PMG HV Pte. Ltd.(1)Held through PMG; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: 100; 2025: 100 | |
| PMG PL Pte. Ltd.(1)Held through PMGPDF p. 131 | Singapore | |
| PMG PL Pte. Ltd.(1)Held through PMG; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: 100; 2025: 100 | |
| PMG RH Pte Ltd. (fka PMG Int 2 Pte. Ltd.)(1)Held through PMGPDF p. 131 | Singapore | |
| PMG RH Pte Ltd. (fka PMG Int 2 Pte. Ltd.)(1)Held through PMG; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: 100; 2025: – | |
| Wellington Pte. Ltd.(4)Held through PMGPDF p. 131 | Singapore | |
| Wellington Pte. Ltd.(4)Held through PMG; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: 100; 2025: – | |
| PMG NV Pte. Ltd. (fka PMG CACTIII Pte. Ltd.) (1)Held through PHSPDF p. 131 | Singapore | |
| PMG NV Pte. Ltd. (fka PMG CACTIII Pte. Ltd.) (1)Held through PHS; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: 35.7; 2025: 35.7 | |
| Ardennes Healthcare Pte. Ltd. (1)Held through PHSPDF p. 131 | Singapore | |
| Ardennes Healthcare Pte. Ltd. (1)Held through PHS; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: 51; 2025: 51 | |
| PMG TH Pte. Ltd. (1)Held through PHSPDF p. 131 | Singapore | |
| PMG TH Pte. Ltd. (1)Held through PHS; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: 51; 2025: 51 | |
| Fidelity Neuroscience Pte. Ltd. (“FNS”)(1)Held through APSPDF p. 131 | Singapore | |
| Fidelity Neuroscience Pte. Ltd. (“FNS”)(1)Held through APS; effective equity held by the Group; 2026 vs 2025PDF p. 131 | 2026: 51; 2025: 51 | |
Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.
Senior executives
| Item | Value | Period / scope | Source |
|---|---|---|---|
| DR. CHUA HSHAN CHER | DEPUTY CHIEF EXECUTIVE OFFICER; HEAD OF FAMILY MEDICINE | PDF p. 9 | |
| MR. WONG QINGYUAN | CHIEF FINANCIAL OFFICER | PDF p. 9 | |
| DR. RACHEL LIM | HEAD OF AESTHETICS AND WELLNESS | PDF p. 10 | |
| DR. SEBASTIAN CHUA | HEAD OF ANAESTHESIOLOGY AND PAIN MANAGEMENT | PDF p. 10 |
Extracted from Livingstone Health Holdings Limited Annual Report 2026 and checked against the cited pages; see the original report for full context.
Related parties, people & properties
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Rental paid | (251,093) S$ | Group; Company related to a director of the Company; 2026 | PDF p. 151 |
| Sales of services to | 19,510 S$ | Group; Company related to a director of the Company; 2026 | PDF p. 151 |
| Administrative income | 76,000 S$ | With an associate; 2026 | PDF p. 151 |
| Sales of services to | 100,616 S$ | With an associate; 2026 | PDF p. 151 |
| Compensation of directors and key management personnel | 8,400,060 S$ | Group; total of short-term and post-employment benefits; 2026 | PDF p. 151 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Contingent liabilities | the Company and certain subsidiaries have given a corporate guarantee to a bank for bank borrowings, Loan 1 to Loan 6 in respect to the banking facilities granted to a subsidiary (Note 22) | Company and certain subsidiaries; as at 31 March 2026 · As at 2026-03-31 | PDF p. 149 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Dr Tay Ching Yit, Wilson | 1,267 S$'000 | Group; total remuneration FY2026 | PDF p. 64 |
| Mr Dax Ng Yung Sern | 292 S$'000 | Group; total remuneration FY2026 | PDF p. 64 |
| Mr Teh Wing Kwan | 42 S$'000 | Group; total remuneration FY2026 | PDF p. 64 |
| Mr Fong Heng Boo | 42 S$'000 | Group; total remuneration FY2026 | PDF p. 64 |
| Mr Chan Yu Meng | 39 S$'000 | Group; total remuneration FY2026 | PDF p. 64 |
| Directors' fees recommended | S$124,000 | Proposed for financial year ending 31 March 2027 | PDF p. 64 |
| Aggregate compensation of four key management personnel | approximately S$1,842,000 | Four key management personnel, FY2026 | PDF p. 65 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Total No. of Employees | 91 employees | Group; as at 31 March 2026 · As at 2026-03-31 | PDF p. 34 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Looking Ahead | the Group remains cautious of the business outlook as the operating environment continues to be challenging with rising business costs | Joint statement by Chairman and CEO | PDF p. 5 |
Extracted from Livingstone Health Holdings Limited Annual Report 2026 and checked against the cited pages; see the original report for full context.
Source: Livingstone Health Holdings Limited Annual Report 2026 ↗
Corporate information